VEGFR-3对脉络膜新生血管的影响及其机制的初步研究

基本信息
批准号:81800850
项目类别:青年科学基金项目
资助金额:21.00
负责人:金恩忠
学科分类:
依托单位:北京大学
批准年份:2018
结题年份:2021
起止时间:2019-01-01 - 2021-12-31
项目状态: 已结题
项目参与者:赵明威,朱莉,鲍璇,王辉杭,桂宇飞
关键词:
年龄相关性黄斑变性血管内皮生长因子受体3视网膜色素上皮细胞脉络膜新生血管
结项摘要

Choroidal neovascularization (CNV) is the leading cause of irreversible serious visual impairment in age-related macular degeneration. Suppression of CNV formation and development is the only effective treatment. It had been proved that vascular endothelial growth factor (VEGF) plays an important role in CNV production but its underlying mechanisms remain unclear. Our previous study found that VEGF receptor 3 was highly expressed in CNV tissues. The decreased expression of VEGFR-3 could inhibit the tube formation. The intravitreal injection of anti-VEGFR-3 antibody could significantly reduce CNV Lesion volume and fluorescence contrast leakage. In order to explore the effect of VEGFR-3 in pathogenesis of CNV, the present study aimed to culture hRVEC cells in vitro with VEGFR-3 overexpression or knockdown to study the effect of different stimuli and VEGFR-3 expression on hRVEC cells; In vitro co-culture of hRVEC and ARPE-19 cells, upregulation or downregulation of VEGFR-3 expression, mimicking the changes of the behavior of vascular endothelial cells. The mouse CNV model was constructed to verify the correlation between VEGFR-3 and CNV, and the retinal choroidal morphology and histopathological changes in mice after VEGFR-3 antagonism were also observed. The expression of ERK1/2, pERK1/2, PI3K and AKT in hRVECs with knockdown or overexpression of VEGFR-3 were collected, and the possible regulatory pathway connected the expression of VEGFR-3 with CNV occurrence and development was explored. This study will provide a new theoretical basis for exploring the pathogenesis of CNV and proving new potential therapeutic targets.

脉络膜新生血管(CNV)是年龄相关性黄斑变性发生不可逆性严重视力损伤的主要致病因素,抑制其生成和发展是目前唯一有效的治疗手段。VEGF在CNV生成中具有重要作用,但机制仍不甚明确。课题组前期研究发现VEGF受体3在CNV组织中高表达;siRNA敲减VEGFR-3抑制内皮细胞成管;VEGFR-3拮抗后CNV病灶容积缩小,渗漏减轻。为探索VEGFR-3在CNV发病中的作用机制,本课题拟通过研究研究不同刺激因素及VEGFR-3表达改变对内皮细胞成管的影响;共培养hRVEC和ARPE-19细胞,调节VEGFR-3表达观察其对血管内皮细胞功能的影响;观察抗VEGFR-3抗体作用后小鼠CNV形态与组织病理学改变;敲减或过表达VEGFR-3情况下检测ERK1/2、PI3K、AKT的表达水平,探索VEGFR-3在CNV中的可能调控通路。该研究将为探索CNV发病机制和新的潜在治疗靶点提供新的理论依据。

项目摘要

脉络膜新生血管(CNV)是年龄相关性黄斑变性发生不可逆性严重视力损伤的主要致病因素,抑制其生成和发展是目前唯一有效的治疗手段。VEGF在CNV生成中具有重要作用,但机制仍不甚明确。前期研究发现VEGFR-3在CNV组织中高表达;siRNA敲减VEGFR-3抑制内皮细胞成管。通过本项目的研究,我们对VEGFR-3在CNV发病中的作用机制进行了进一步的探讨。研究探索了炎症及促炎因子IFNγ通过RPE细胞表达VEGF-R3在CNV中发挥的作用,发现炎症刺激(IFNγ)可以导致RPE的VEGF-R3和VEGF-C表达均升高,初步阐释了其在RPE细胞中发挥的作用。此外,IFNγ处理同样可以上调HUVECs细胞的VEGF-R3表达。在体外培养siRNA 敲减VEGFR-3表达的hRVEC细胞中,给予不同浓度VEGF-A、VEGF-C、IFNγ处理,研究不同刺激因素及VEGFR-3表达改变对hRVEC细胞成管作用的影响,并明确不同刺激因素和VEGFR-3表达在内皮细胞成管过程中的协同或拮抗作用。此外,还通过小鼠CNV模型的玻璃体腔注射抗VEGFR-3抗体作用,观察小鼠CNV形态与组织病理学改变。总的来说,本项目的初步研究结果阐述了血管内皮细胞生长受体3(VEGFR-3)在脉络膜新生血管形成中的可能作用机制,且玻璃体腔注射抗VEGER-3抗体可以减小CNV病灶容积,这为CNV提供了潜在的新治疗靶点和理论依据。

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

Protective effect of Schisandra chinensis lignans on hypoxia-induced PC12 cells and signal transduction

Protective effect of Schisandra chinensis lignans on hypoxia-induced PC12 cells and signal transduction

DOI:10.1080/15287394.2018.1502561
发表时间:2018
2

Efficient photocatalytic degradation of organic dyes and reaction mechanism with Ag2CO3/Bi2O2CO3 photocatalyst under visible light irradiation

Efficient photocatalytic degradation of organic dyes and reaction mechanism with Ag2CO3/Bi2O2CO3 photocatalyst under visible light irradiation

DOI:
发表时间:2016
3

基于 Kronecker 压缩感知的宽带 MIMO 雷达高分辨三维成像

基于 Kronecker 压缩感知的宽带 MIMO 雷达高分辨三维成像

DOI:10.11999/JEIT150995
发表时间:2016
4

Engineering Leaf-Like UiO-66-SO_3H Membranes for Selective Transport of Cations

Engineering Leaf-Like UiO-66-SO_3H Membranes for Selective Transport of Cations

DOI:10.1007/s40820-020-0386-6
发表时间:2020
5

The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects

The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects

DOI:10.3389/fcell.2021.735374
发表时间:2021

金恩忠的其他基金

相似国自然基金

1

脉络膜血管内皮细胞的miRNA表达及其对脉络膜新生血管形成的调控研究

批准号:81371023
批准年份:2013
负责人:范玮
学科分类:H1305
资助金额:16.00
项目类别:面上项目
2

Fibulin-5对脉络膜新生血管的阻抑及其对AMD修复机制的研究

批准号:30801270
批准年份:2008
负责人:李付亮
学科分类:H1305
资助金额:20.00
项目类别:青年科学基金项目
3

CD26调控骨髓来源细胞对脉络膜新生血管的作用及其机制研究

批准号:81500748
批准年份:2015
负责人:李红
学科分类:H1305
资助金额:18.00
项目类别:青年科学基金项目
4

脉络膜新生血管形成中Annexin A2的调节机制

批准号:30772395
批准年份:2007
负责人:赵世红
学科分类:H1305
资助金额:28.00
项目类别:面上项目